Biocon Biologics partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

Zydus Lifesciences Q3 FY24 PAT up 26.8%

Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.

Novartis to acquire MorphoSys AG for Euro 2.7 billion to strengthen oncology pipeline

Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement

Growth of Ayush sector is bound to happen: Kotecha

Ayush is expanding beyond wellness to therapeutic wellness

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore

Qure.ai adds new FDA breakthrough device status for qSpot-TB

4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months

Mansukh Mandaviya addresses 37th STOP TB Partnership Board Meeting

Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace

WACKER to exhibit new adhesive, medical solutions at MD&M West

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM

American Cancer Society and Pfizer announce a US $15 million initiative to bridge the gap in cancer care disparities

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support